AINTZANE
GARCIA BEA
INVESTIGADOR/A EN FORMACION
Researcher in the period 2012-2013
Publications (10) AINTZANE GARCIA BEA publications
filter_list
2021
-
Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity
European Journal of Medicinal Chemistry, Vol. 209
-
Opposite alterations of 5HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile
Translational Psychiatry, Vol. 11, Núm. 1
2019
-
Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins
European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463
2017
-
A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding
Journal of Psychopharmacology, Vol. 31, Núm. 12, pp. 1519-1526
-
Antipsychotic-induced Hdac2 transcription via NF-ΰ B leads to synaptic and cognitive side effects
Nature Neuroscience, Vol. 20, Núm. 9, pp. 1247-1259
2016
-
Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia
Science Signaling, Vol. 9, Núm. 410
-
Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study
Schizophrenia Research, Vol. 177, Núm. 1-3, pp. 18-27
-
Novel targets for drug treatment in psychiatry
The Medical Basis of Psychiatry: Fourth Edition (Springer New York), pp. 601-654
-
Substituted conformationally restricted guanidine derivatives: Probing the α2-adrenoceptors’ binding pocket
European Journal of Medicinal Chemistry, Vol. 123, pp. 48-57
2013
-
Repressive epigenetic changes at the mglu2 promoter in frontal cortex of 5-HT2A knockout mice
Molecular Pharmacology, Vol. 83, Núm. 6, pp. 1166-1175